Organic Active Ingredients TRIZ Cases

Combined TGF-β1/TGF-β2 and CTGF therapy promotes collagen repair in injured connective tissue while helping reduce swelling and pain.

Room-stable fibrinogen and thrombin solutions cut thawing steps, extend usability, and reduce waste of scarce fibrinogen.

Blood mRNA is reverse transcribed and optically detected to distinguish bacterial, viral, and non-infectious ARI causes for better treatment.

Sequential cord blood Treg isolation and IL-2/CD3-CD28 expansion create a ready cell therapy to suppress auto-reactive T cells and inflammation.

Peripherally restricted CB1 antagonists block receptors in metabolic tissues while avoiding blood-brain barrier penetration and CNS side effects.

Oral cG-2-AllylP restores IGF-1, normalizes AKT and ERK, and rescues dendritic defects linked to Pitt Hopkins syndrome.

Targeting PKR or eIF2α phosphorylation can suppress toxic RAN protein translation while helping preserve normal translation in repeat-expansion diseases.

These aromatic compounds improve glycemic control and lower plasma insulin while helping prevent hepatic fibrosis and steatosis.

Lipid and amino acid surface treatment controls silicon nanoparticle hydrolysis, stabilizing orthosilicic acid and active-agent release.

A sublingual eliglustat composition bypasses first-pass metabolism to raise bioavailability, reduce dosing, and speed therapeutic effect.

Acylated glucagon analogues use fatty-chain peptide tuning to balance GLP-1 and glucagon receptor activity for weight loss and glucose control.

A 0.45 μm pre-filter and 0.2 μm sterilizing filter keep timolol gel sterile while controlling viscosity and avoiding heat damage.

SBEβCD inclusion complexing with bicarbonate raises meloxicam solubility and absorption, supporting faster, sustained relief for migraine pain.

A softgel combining curcumin, carotenoids, omega-3s, vitamin E, and zinc improves macular pigment support, glare recovery, and visual speed.

Oral masitinib targets sickle cell crises and acute chest syndrome when current therapies are inadequate or unsuitable for some patients.

A thin ocular film uses a biocompatible liquid depot to resist tears and release drug steadily for days without vision impairment.

Stealth polymer-coated protein nanoparticles enable inhaled siRNA and antibody delivery with better lung targeting, uptake, and nuclease protection.

Local nanocarrier delivery of immunosuppressants with therapeutic macromolecules reduces Type I and IV hypersensitivity while limiting systemic side effects.

Crystalline acid salts of an FGFR inhibitor improve handling, storage stability, purification, dissolution, and bioavailability for cancer formulations.

Critically spaced tiopronin pulses lower peak blood levels while sustaining urinary exposure to control nighttime cystine and reduce side effects.

Tricyclic amide EZH2 inhibitors improve selectivity and pharmacodynamic effects through targeted scaffold and substitution design.

Polymer-based amorphous dispersions stabilize oily ITI-007, prevent crystallization, and maintain over 90% stability under heat and humidity.

Analyte signatures from blood, saliva, urine, or stool help match obesity phenotypes to drug treatments with more consistent weight loss and fewer side effects.

Liver-targeted polymethine dye nanocarriers deliver PKC inhibitors for septic cholestasis while limiting systemic immune suppression and dose.

Spray-dried amorphous adrenaline powder with maltodextrin improves stability, shelf-life, and rapid intranasal absorption.

Combining a RIG-I agonist with PD-1 or PD-L1 blockade boosts interferon signaling, delays tumor growth, and limits inflammatory side effects.

Specific bacterial strains boost vitamin D absorption and serum levels faster while avoiding the cholesterol-related limits of conventional therapy.

Non-covalent albumin binding improves ophthalmic drug solubility and reduces burning and stinging while maintaining treatment efficacy.

Controlled sulfation of gluco-galacto-oligosaccharides inhibits factor Xa and thrombin generation while limiting bleeding risk.

A vaccinia-inflamed rabbit skin extract is paired with cytotoxic drugs to reduce side effects while preserving anti-tumor activity.

Oral riluzole prodrugs resist rapid hepatic metabolism and release riluzole in plasma for more predictable exposure and fewer liver-related effects.

CoQ10 co-administration helps protect healthy cells during chemotherapy, reducing side effects while supporting tumor reduction and survival time.

Trisulfide compounds strengthen HGF-c-Met binding to boost HGF-driven cell proliferation and physiological activity for regenerative therapy.

A guanidine derivative composition promotes hair growth and follicle regeneration while avoiding the side effects of surgery and minoxidil.

Combining 5% minoxidil with 0.07-0.095% finasteride in foam or liniment improves alopecia response speed while limiting irritation and side effects.

Phthalazinone-based modulators vary core substituents and ring structures to kill cancer cells and inhibit proliferation across cancer types.

Antibody capture plus peptide mass spectrometry enables sensitive UBE3A quantification for Angelman syndrome diagnosis and therapy monitoring.

Serological screening and elevated CRP or ESR guide secukinumab dosing to improve response and sustained joint symptom control.

Machine learning-guided in silico screening narrows millions of compounds to validated antibacterial candidates, cutting discovery time and cost.

Structured CBC derivatives expand treatment across cancer, neurological disorders, and pain while enabling more controlled dosing.

Amorphous dasatinib dispersions use polymer matrices to maintain oral exposure despite elevated gastric pH or acid-reducing co-therapy.

Pyridine derivatives use targeted substitutions to block CCR2/CCR5 while avoiding CYP450 inhibition, improving inflammatory disease drug safety.

3-benzoyl-pyrrolopyridine derivatives selectively inhibit MKK4 over MKK7 and JNK1 to promote liver regeneration and reduce hepatocyte death.

Non-nucleoside bicyclic pyridone compounds inhibit herpesvirus DNA polymerases to address resistance and reduce side effects.

Targeted dsRNA silences ANGPTL3 mRNA through RNA interference, lowering serum lipids, triglycerides, and cholesterol.

Deuterium-enriched gaboxadol extends therapeutic benefit in developmental disorders while lowering peak plasma exposure and reducing dosing frequency.

Using the hydrogen sulphate salt in a carrier matrix improves solubility, dissolution, and storage stability for reliable bioavailability.

Effector-activated allosteric antibodies restore antigen binding at the target site, reducing systemic side effects and infection risk.

Water extraction of sweet basil polyphenols and triterpenes creates a low-cost topical or oral composition that inhibits HSV and speeds ulcer healing.

Monohydrate crystal forms MH1 and MH2 improve PDE9 inhibitor solubility, oral bioavailability, and physical stability for oral dosing.

A two-phase ganaxolone titration reaches 75–175 ng/ml plasma levels to support seizure control and tolerability with CBD.

Esterified cromolyn crosses intestinal membranes as an oral prodrug, then releases active cromolyn to improve bioavailability.

This case combines riluzole or trigriluzole with PD-1, PD-L1, or CTLA-4 inhibitors to address limited survival and response.

Artificial microRNA clusters target multiple pathways to improve gene regulation therapy.

This case uses buffered, premixed nicardipine at 0.1 mg/mL to avoid dilution time, contamination risk, and dosage errors.

Heterocyclic compounds target mutant KRAS G12D and G12V to control cancer cells while preserving wild-type KRAS function.

A fused heterocyclic molecule framework preserves Btk inhibition against C481S mutants and expands treatment options.

This case uses pyrazoline compounds to block peripheral CB1b receptors for obesity treatment while limiting brain CB1 effects.

This case uses site-specific deuteration to improve bioavailability, reduce hERG interaction, and support less frequent dosing.

This case combines antibiotic, ketoprofen, and lidocaine in a topical cream for cellulitis treatment and pre-operative infection prevention.

This case examines CFTR correctors and potentiators that improve F508del trafficking, channel activity, and ion transport.

This aqueous formulation shifts esketamine delivery from nasal spray to oral mucosa to limit irritation and improve bioavailability.

This case combines PKC and MDM2 inhibitors to address limited single-agent efficacy and induce tumor regression in uveal melanoma.

This case isolates Quercus infectoria tannins and targets MMP-2, NF-κB p65, and RhoA in oral cancer treatment.

Micronized particles can agglomerate; a fixed-dose lactose-carrier formulation supports lung delivery and longer in-use shelf-life.

This case uses one inhibitor strategy to target BRAF, CRAF, and RAF dimers while limiting paradoxical signaling in cancers.

Polymer microparticles limit initial moxidectin release and maintain effective levels for three months with less injection-site pain.

Intranasal inhibitor combinations target SARS-CoV-2 in respiratory tissues with lower drug amounts.

This case uses modified AAV9 capsids and DUX4-FL-binding miRNA to silence DUX4 in muscle while limiting liver exposure.

pH-responsive ionizable compounds form nanoparticles that protect nucleic acids and improve cellular uptake with lower toxicity.

Low PD-L1 expression limits colorectal cancer therapy; estrogen enhances anti-PD-L1 activity and M1 macrophage levels.

Dual-target radiolabeled antibodies address chemoresistance and leukemia stem cells.

Specific pyridazine or pyrimidine ring structures tune BTK binding to support effective signaling modulation with fewer off-target effects.

Potent SAE inhibitor compounds target SUMO activation to modulate sumoylation pathways for hematologic and solid tumors.

This case uses fucosylated and sialylated LacNAc-core HMOs to modulate gene expression, lipolysis, and cholesterol levels.

This case uses 5'-cyclopropylene nucleosides at selected gapmer positions to reduce toxicity while preserving gene regulatory efficacy.

This case uses crospovidone and croscarmellose sodium to replace extended release agents and support oral or sublingual use.

This case uses PRC1 and PRC2 inhibitors to mature CCM-deficient endothelial cells and prevent cavernoma formation in models.

Novel small-molecule GLP-1R agonists address injection limits with oral bioavailability and improved glucose tolerance.

This case uses early caspase-1 or pan-caspase inhibition to limit pyroptosis, inflammation, and severe COVID-19 progression.

CPP-linked antisense oligomers bypass mRNA decay by skipping exon 45, restoring the reading frame for functional dystrophin.

Specific ethanol, polyethylene glycol, and water ratios stabilize liquid nimodipine under heat and humidity while reducing impurities.

This case shows how organoids self-assemble around ultracompact RFID sensors for wireless tracking without impairing native tissue function.

Dibromomaleimide linkers re-bridge antibody disulfides for stable, homogeneous ADCs with controlled payload distribution.

This case develops small-molecule GLP-1R agonists with improved pharmacokinetics for oral dosing and glucose tolerance.

Water pretreatment lowers crosslinker formation in glycerol carbonate (meth)acrylate.

This case uses a shared pyrrolopyrazole core and variable substituents to diversify P-CAB structures while preserving acid inhibition.

This case uses pyrrolopyrimidine structures to inhibit BTKC481S, improve TMD8 activity, and increase tumor inhibition in models.

This case replaces injectable peptide therapy with oral GLP-1R agonists designed for stability, absorption, and glucose control.

This SNA design combines class A and B CpG sequences in one shell to coordinate delivery and immune activation.

Barrier biomarkers classify IBD dysfunction severity, guiding anti-TNF, anti-integrin, and other targeted therapies.

This case replaces surgery and minoxidil with a guanine derivative that supports hair follicle regeneration and sustained growth.

Natural O/W emulsion complexes form responsive hydrogels that deliver nutrients and pharmaceuticals to the small intestine.

Systematically varied quinoline structures inhibit KRAS activity, addressing limited treatment options for KRAS-mutated cancers.

This case shows how pyridyl compounds form nicorandil in vivo to protect renal tissue from ischemic and drug-induced injury.

This case develops selective cathepsin K inhibitors with fast off-rates for prolonged treatment of bone and cartilage disorders.

This case develops XRPD-defined RSK inhibitor crystal forms to improve stability and solubility while addressing drug resistance.

This case shows how a substituted tricyclic core targets IRAK4 while addressing weak kinase selectivity in autoimmune and tumor therapy.

This case uses controlled psilocybin doses with psychological support to target neurological disorders, chronic pain, and inflammation.

13-membered azalides down-regulate TNFα and IL-6 to control inflammation without antibacterial resistance pressure.

C5-C6-oxacyclic fused iminothiazine dioxide compounds with an ether linker inhibit BACE enzymes to reduce Aβ production and improve inhibitor potency.

Ketal-linked hydrocarbon chains enable self-assembling lipophilic cores that improve delivery efficiency while reducing cell toxicity.

Oligonucleotide compounds link antisense strands at 5' ends to inhibit miRNA activity with enhanced potency.

SU056 azopodophyllotoxin analog inhibits YB1 to overcome treatment resistance in ovarian cancer.

GSDMD inhibitors target gasdermin D to prevent aortic rupture and address limited treatment efficacy.

Accelerated stability testing detects impurities in sodium lauryl sulfate batches to enable precise quality sorting for pharmaceutical formulations.

Cyclodextrin inclusion complexes stabilize trace elements, resolving bioavailability and formulation stability trade-offs.

A sterile pharmaceutical aerosol composition solubilizes poorly water-soluble active agents using non-ionic surfactants and phospholipids.

A nasal preparation combines crystalline cellulose with tricalcium phosphate to enhance powder fluidity for automated manufacturing.

A sustained-release naltrexone dosage form controls plasma concentration profiles using specific polymer carriers.

Lipid nanoparticles carrying mRNA with microRNA binding sites achieve targeted organ delivery while reducing toxicity from viral vectors.

Rostatfuroxin stabilizes nephrin and synaptopodin via local quality design, resolving insufficient proteinuria reduction in normotensive patients.

A method synthesizing N-(bromoacetyl)-3,3-dinitroazetidine using aqueous extraction to separate impurities from the organic phase.

Pyrimidine-based inhibitors overcome enzalutamide resistance in castration-resistant prostate cancer by suppressing AR expression.

Heterochimeric antibodies combine donor variable regions with target species constant regions to maintain antigen binding specificity.

Antibody-linked oligonucleotide complexes deliver exon skipping payloads to muscle cells via receptor-mediated internalization.

Pyridinone compounds target fibrotic pathways to treat idiopathic pulmonary fibrosis, addressing limited treatment options.

A Markov Chain-based inventory planner evaluates candidate policies to determine optimal reorder points, reducing computational time while maintaining accuracy.

Senaparib traps PARP-DNA complexes while intermittent low-dose TMZ induces lesions, reducing hematological toxicity in solid tumors.

Administering high-dose oral zoledronic acid monthly treats inflammatory pain while avoiding complex formulation systems.

Pyrazole derivatives inhibit tyrosine kinase activity of fibroblast growth factor receptors to disrupt signaling pathways in cancer treatment.

Nicotine lozenge compositions with reduced alkaline buffering agents optimize oral pH and enhance rapid nicotine absorption through the oral cavity.

An amorphous glassy coating on a microprojection array prevents dislodgment during insertion while enabling controlled drug release through hydration.

Amorphous psilocybin formulation resolves crystallization flow issues while maintaining chemical purity under harsh storage conditions.

A composition combining fish oil, willow bark extract, and vitamin E targets platelet aggregation and intrinsic clotting pathways.

Direct adventitial injection of cell division inhibitors and glucocorticoids prevents vessel thickening and stiffening after mechanical revascularization.

Modular Formula I compounds inhibit Factor XIa, resolving potency and pharmacokinetic trade-offs in thrombosis treatment.

Segmented pyrazolo[1,5-a]pyrimidine structures optimize PAR2 inhibition to resolve limited treatment options for atopic dermatitis and Crohn's disease.

Synthetic triterpenoid derivatives replicate natural bioactivity while eliminating variable plant sources to ensure consistent supply.

Iron and manganese porphyrins act as superoxide dismutase mimetics to treat chronic itch without exacerbating skin damage from scratching.

2-Iminobiotin reduces cognitive impairment from cerebral hypoxia-ischemia by inhibiting nitric oxide synthase pathways.

Determining stromal caveolin-1 and caveolin-2 protein levels via immunohistochemical staining enables precise risk stratification for breast cancer patients.

Bifunctional compounds recruit STAT proteins to E3 ubiquitin ligases, enabling targeted degradation of transcription factors that resist conventional therapies.

Modified beta-sitosterol compounds enable internal administration to treat neurodegenerative diseases while maintaining low production costs.

Oil-in-water microemulsion overcomes poor water solubility and permeation barriers to deliver clobazam through skin.

Radiation-treated bacterial cellulose provides a biodegradable membrane for medical implant applications.

Chlorite administration converts activated macrophages to an inactivated state, resolving the contradiction between immune defense and tissue damage.

Esterification of S-butylphthalide creates water-soluble salts for safe intravenous delivery.

Developing novel solid forms of an MK2 inhibitor improves aqueous solubility and stability to overcome poor bioavailability in kinase inhibition.

An integrated mobile drug rack replaces manual narcotic logging with automated electronic tracking to eliminate inventory inaccuracies.

Composition of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan stimulates proteoglycan production.

Inhibiting PDE1A and PDE1C enzymes reduces toxic alpha-synuclein aggregates, addressing the lack of effective therapies for neurodegenerative diseases.

Merging raspberry extract and hydroxyproline overcomes the trade-off between natural ingredient safety and insufficient elastase inhibition.

Formula I compounds inhibit acetyl-CoA carboxylase to reduce malonyl-CoA levels, addressing insufficient efficacy and safety in current obesity treatments.

Combines phenolic derivatives with benzodiazepine systems to target multiple pathological mechanisms simultaneously.

Segmented stop codon mutations in the S9 gene segment prevent reassortment while maintaining replication competence for effective immunity.